Literature DB >> 22841163

Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriage.

Tu'uhevaha J Kaitu'u-Lino1, Laura Tuohey, Stephen Tong.   

Abstract

A shift from type 1 to type 2 immune bias is essential for successful implantation and pregnancy. ST2 is a receptor present on type 2 immune cells and IL-33 was recently discovered to be its ligand. We measured serum levels of soluble ST2 (sST2) and IL-33 across the mid-first trimester and examined whether levels were dysregulated among women with a viable fetus but destined to miscarry. While there was no significant change in sST2 or IL-3 across the first trimester, we found that women with live pregnancies destined to fail had dysregulated levels of serum IL-33, and potentially sST2 at six weeks' gestation.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22841163     DOI: 10.1016/j.jri.2012.06.003

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  9 in total

1.  Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study.

Authors:  Roberto Romero; Piya Chaemsaithong; Adi L Tarca; Steven J Korzeniewski; Eli Maymon; Percy Pacora; Bogdan Panaitescu; Noppadol Chaiyasit; Zhong Dong; Offer Erez; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2017-03-01

2.  An imbalance of the IL-33/ST2-AXL-efferocytosis axis induces pregnancy loss through metabolic reprogramming of decidual macrophages.

Authors:  Yan-Ran Sheng; Wen-Ting Hu; Hui-Hui Shen; Chun-Yan Wei; Yu-Kai Liu; Xiao-Qian Ma; Ming-Qing Li; Xiao-Yong Zhu
Journal:  Cell Mol Life Sci       Date:  2022-03-04       Impact factor: 9.261

3.  Maternal IL-33 critically regulates tissue remodeling and type 2 immune responses in the uterus during early pregnancy in mice.

Authors:  Nuriban Valero-Pacheco; Eric K Tang; Noura Massri; Rachel Loia; Anat Chemerinski; Tracy Wu; Salma Begum; Darine W El-Naccache; William C Gause; Ripla Arora; Nataki C Douglas; Aimee M Beaulieu
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-22       Impact factor: 12.779

4.  Protective role of IL33 signaling in negative pregnancy outcomes associated with lipopolysaccharide exposure.

Authors:  Keisuke Kozai; Khursheed Iqbal; Ayelen Moreno-Irusta; Regan L Scott; Mikaela E Simon; Pramod Dhakal; Patrick E Fields; Michael J Soares
Journal:  FASEB J       Date:  2021-02       Impact factor: 5.191

5.  Decreased IL-33 Production Contributes to Trophoblast Cell Dysfunction in Pregnancies with Preeclampsia.

Authors:  Hong Chen; Xiaobo Zhou; Ting-Li Han; Philip N Baker; Hongbo Qi; Hua Zhang
Journal:  Mediators Inflamm       Date:  2018-03-15       Impact factor: 4.711

6.  Differences in maternal soluble ST2 levels in the third trimester of normal pregnancy versus preeclampsia.

Authors:  Prameswari Hawani Sasmaya; Achmad Fitrah Khalid; Dewi Anggraeni; Setyorini Irianti; Mohammad Rizki Akbar
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2021-12-07

7.  Disordered IL-33/ST2 activation in decidualizing stromal cells prolongs uterine receptivity in women with recurrent pregnancy loss.

Authors:  Madhuri S Salker; Jaya Nautiyal; Jennifer H Steel; Zoe Webster; Sandra Sućurović; Marilena Nicou; Yogesh Singh; Emma S Lucas; Keisuke Murakami; Yi-Wah Chan; Sean James; Yazan Abdallah; Mark Christian; B Anne Croy; Biserka Mulac-Jericevic; Siobhan Quenby; Jan J Brosens
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

8.  Genetic variant in IL-33 is associated with idiopathic recurrent miscarriage in Chinese Han population.

Authors:  Jun Yue; Yu Tong; Lan Xie; Tao Ma; Jiyun Yang
Journal:  Sci Rep       Date:  2016-03-30       Impact factor: 4.379

9.  A bioplex analysis of cytokines and chemokines in first trimester maternal plasma to screen for predictors of miscarriage.

Authors:  Natalie J Hannan; Katerina Bambang; Tu'uhevaha J Kaitu'u-Lino; Justin C Konje; Stephen Tong
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.